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ABSTRACT 10 
Oral delivery of amphotericin B (AmpB) is desirable because it provides a more patient-friendly 11 
mode of administration compared to the current delivery approach akin with the marketed AmpB 12 
formulations. The goal of the study was to investigate the pharmacokinetics and tissue distribution 13 
of orally administered chitosan-coated AmpB-loaded nanostructured lipid carriers (ChiAmpB NLC) 14 
administered to were evaluated in Sprague Dawley rats at a dose of 15 mg/kg. Orally administered 15 
ChiAmpB NLC resulted in demonstrated a two-fold increase in the area under the curve (AUC0-) 16 
compared to the uncoated AmpB NLC and marketed Amphotret®. This enhanced bioavailability of 17 
AmpB suggests prolonged transit and retention of ChiAmpB NLC within the small intestine through 18 
mucoadhesion and subsequent absorption by the lymphatic pathway. The results show that   The 19 
mean absorption and residence times (MAT & MRT) were both significantly higher from ChiAmpB 20 
NLC compared to the other two formulations, which attesting to the mucoadhesive effect. The 21 
ChiAmpB NLC presented a lower nephrotic accumulation with preferential deposition in liver and 22 
spleen. Thus, the limitations of current marketed IV formulations of AmpB are potentially addressed 23 
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INTRODUCTION 29 
 Oral administration of AmpB appeals to clinicians and patients alike because of the potential 30 
of eliminating the toxicities (notably nephrotoxicity) associated with the current mode of delivery, 31 
which is exclusively by intravenous (IV) administration. It is also bound to reduce treatment cost and 32 
improve the quality of life of the patients (1,2). However, due to the poor solubility and permeability 33 
of challenging physicochemical properties of AmpB, oral delivery of AmpB results in a meager 34 
bioavailability (< 0.3 %) which limits its therapeutic efficacy (3,4). Poor oral absorption of AmpB has 35 
long been reported in different animal trials such as in rats (5,6), mice (7) and dogs (8). 36 
Nanotechnology seems to be the key to unlocking some of the constraints associated with the 37 
administration of Amp orally. However, with the introduction of the nanotechnology, there is a ray 38 
of hope to developing a safer, yet effective oral formulation of AmpB.  39 
Upon oral administration, most drugs are absorbed from the small intestine to the systemic 40 
circulation via the portal blood vein. However, for lipid formulations or hydrophobic drugs, intestinal 41 
lymphatic pathway provides an alternative route, which bypasses the hepatic first pass metabolism 42 
at the liver and results in improved bioavailability (9–11). Additionally, this route portrays a 43 
distinctive characteristic whereby the transportation of the drug occurs over a longer period of time 44 
compared to the portal vein route. Thus, lymphatic pathway can be exploited for prolonged delivery 45 
of therapeutic agents to the systemic circulation (12). 46 
 The goal of the In the this  present investigation was to formulate nanostructured lipid 47 
carriers (NLCs) comprised of beeswax and coconut oil were used as the carrier system for the oral 48 
delivery of AmpB with the aim to exploit the intestinal lymphatic pathway (13,14). A further aim was 49 
to Additionally, chitosan was coat ed the formulation in order to impart mucoadhesive capability so 50 
that the particles are retained longer during transit in the small intestine. The delayed transit will 51 
 
ensure that most of the particles are taken-up. This way, the bioavailability of AmpB would be 52 
improved.  53 
The pharmacokinetic behaviour of the marketed formulation of AmpB, Fungizone® 54 
administered intravenously was reported to exhibit a complex plasma profile, with a rapid fall in 55 
plasma concentration followed by a long elimination half-life (approximately 15 days). In contrast, 56 
the pharmacokinetic behaviour of orally administered AmpB is less known. It is administered orally 57 
to treat localized gastrointestinal (GI) tract infections mainly due to the poor absorption profile. It 58 
was reported that administration of high doses of AmpB (2 - 10 g daily) to humans resulted in 59 
similarly low plasma concentration levels as doses of 30 - 40 mg per day (7,15).  60 
Tissue distribution studies on newly developed formulations is necessary since it provides 61 
information on the potential tissue accumulation of the formulation and/or the drug. Tissue 62 
accumulation thus, provides insights on potential toxicity or efficacy of the formulation. In this 63 
regard, determination of the plasma level of the AmpB alone is insufficient because there is a poor 64 
correlation between the plasma level and biodistribution of the active in the organs (16,17). 65 
Evaluation of levels of AmpB in the kidneys is crucial because it relates to nephrotoxicity and is the 66 
major limitation to the clinical use of AmpB (15,18). Reticuloendothelial organs (RES) such as liver 67 
and spleen are the target organs for the Leishmania genus, an intracellular parasite which causes 68 
high fatality if left untreated. Currently, AmpB is used as the second-line therapy for visceral 69 
leishmaniasis which comes after parental administration of pentavalent antimony organic 70 
compounds which are associated with high frequency of resistance and side effects (19). Hence, an 71 
accumulation of the AmpB at the aforementioned sites provides an added advantage in terms of 72 
targeting strategy. 73 
Henceforth, in the present study, we aimed to evaluate the i) pharmacokinetic profiles of 74 
AmpB from ChiAmpB NLC in comparison to uncoated AmpB NLC and the marketed formulation, 75 
Amphotret®, ii) retrospectively investigate the mucoadhesion behaviour of ChiAmpB NLC in vivo 76 
 
through analyses of the levels of AmpB in the stomach and small intestine over time and iii) 77 
investigate the tissue distribution of the AmpB in organs-of-interests; kidneys, liver and spleen. 78 
MATERIALS AND METHODS 79 
Materials 80 
 Beeswax and coconut oil were from Acros Organics, New Jersey, USA. Chitosan (low 81 
molecular weight) and phosphate buffered saline tablets (PBS) were purchased from Sigma Aldrich 82 
Co. LLC., Missouri, USA. AmpB and ethylenediaminetetracetic acid, disodium salt dihydrate (EDTA) 83 
were obtained from Fisher Scientific, India. The commercial formulation of AmpB deoxycholate 84 
(Amphotret®, Bharat Serums and Vaccines Limited, India) was a gift from Pahang Pharmacy, 85 
Malaysia. Soya lecithin was purchased from MP Biomedicals (Illkirch, France) and acetic acid was 86 
obtained from R & M Chemicals, India. 1-amino 4-nitronapthalene (≥ 97 %) was obtained from 87 
Apollo Chemicals, San Pedro Sula. All reagents and solvents used of analytical and HPLC grades 88 
respectively. Deionized water used was Milli-Q 18.2 MΩ.cm at 25 °C (Millipore Corp., Bedford, USA).  89 
Methods 90 
Formulation of ChiAmpB NLC formulation 91 
The ChiAmpB NLC was formulated as recently reported (13,14). Briefly, beeswax and 92 
coconut oil were melted at 70 °C before the addition of AmpB and at the same time, Tween-80 and 93 
lecithin were mixed with 10 mL of deionized water and stirred at 70 °C at 500 rpm for 45 minutes. 94 
The surfactant mixture was added into the melted lipids containing AmpB followed by 95 
homogenization at 12 400 rpm for 8 minutes using high speed homogenizer (Ultra-Turrax T25, 96 
Germany). The coarse emulsion was further subjected to probe ultrasonication (Q500 QSonica, 97 
Newtown, CT, USA) for further 8 minutes at 20 % amplitude. The mixture was poured into 4 °C 98 
deionized water under 500 rpm of stirring, making up a total of 100 mL. Chitosan (dissolved in 1 % 99 
v/v acetic acid) was added in a dropwise manner into the formed AmpB NLC in 1: 40 v/v under 100 
stirring of 250 rpm or 15 minutes.  101 
 
The physical properties of the formulation were characterized in terms of particle size, 102 
polydispersity index, zeta potential, encapsulation efficiency and aggregation states as reported 103 
previously (13,14).  104 
High performance liquid chromatography (HPLC) conditions and validation 105 
An Agilent HPLC system (1260 Series, Waldbronn, Germany) equipped with a 15 cm x 4.6 106 
mm reversed-phase C-18 column, Hypersil Gold (ThermoFisher Scientific, Waltham, United States) 107 
with 5 µm particle size stationary phase was used in this study. A mixture of 60 % 2.5 mM EDTA and 108 
40 % acetonitrile was used as the mobile phase at a flow rate of 1.5 mL/min with the wavelength set 109 
at 408 nm.  110 
Calibration curves of AmpB in plasma and tissue were established over 0.1 – 10 µg/mL for 111 
plasma and 1 – 100 µg/g for tissue samples, with at least six data points were used to construct the 112 
curves. The HPLC method was further validated in terms of linearity, recovery, accuracy, precision, 113 
limit of detection (LOD) and limit of quantification (LOQ). 114 
Animals  115 
 In this section was a probe investigation on the performance of the ChiAmpB NLC therefore, 116 
we tried to minimize the number of animals used for the study as much as possible. 12 adult male 117 
Sprague Dawley (268.4 ± 11.1 g) rats used in the pharmacokinetic and tissue distribution studies 118 
were obtained from University Putra Malaysia (UPM). The studies were carried out at The 119 
Comparative Medicine and Technology Unit (COMeT), UPM and approved by the Ethics Committee 120 
of The University of Nottingham (UNMC 19). The rats were housed in ventilated cages at ambient 121 
temperature, maintained under 12/ 12 light-dark cycle and supplied with food and water ad libitum. 122 




Drug administration and blood sampling 126 
 The rats were fasted for 12 hours overnight and then divided into four groups, with three 127 
rats per group. Each group received either one of the following single dose: i) oral gavage of AmpB 128 
NLC, ii) ChiAmpB NLC and iii) Amphotret® at 15 mg/kg of AmpB in 2 mL. The fourth group (iv) was 129 
administered 150 µL of Amphotret® (IV) at a dose of 1.0 mg/kg. The rats were allowed free access to 130 
water throughout the study and food was allowed 4-hour post-dosing. The animals were slightly 131 
anaesthetized with diethyl ether at a dose of 5 g/kg prior to blood sampling. A 500 µL aliquot of 132 
blood was collected from the tail of the rats and transferred to a Microtainer® coated with EDTA at 133 
0, 1, 2, 4, 5, 6, 8 and 24 hours for the orally administered group and 5, 30 minutes, 1, 2, 6, 8 and 24 134 
hours following IV administration. The blood samples were centrifuged at 14 000 rpm (14 463 x g) 135 
for 10 minutes and the supernatant (plasma) was pipetted transferred out carefully and placed in 136 
normal microcentrifuge tubes and . The samples were stored at -20 °C until further analyses were 137 
carried out. 138 
Analyses of plasma and tissue samples 139 
The concentrations of AmpB in the plasma and tissue were analyzed according to a 140 
developed HPLC method. Prior to analysis, a 100 µL aliquot of plasma sample was deproteinized 141 
using 100 µL of methanol containing 13.34 µg/mL of 1-amino 4-nitronaphthalene (IS). The mixture 142 
was vortex-mixed for 5 minutes and then centrifuged at 14 000 rpm (14 463 x g) for 10 minutes. 50 143 
µL of the supernatant was then injected into the HPLC system.  144 
At predetermined time post administration, the rats were humanely sacrificed and the 145 
stomach, small intestine, liver, kidney and spleen were removed after abdominal incision. The 146 
organs were pat-dried with laboratory tissue roll, weighed and homogenized using a high speed 147 
homogenizer (Ultra-Turrax T-25, Germany) at 24 000 rpm for 8 minutes under ice with PBS (pH 7.4) 148 
making up tissue concentration of 0.25 g/mL. The mixture was further ultrasonicated at 20 % 149 
amplitude for 8 minutes. A 100 µL aliquot of tissue homogenate was mixed with 400 µL of methanol 150 
 
containing IS (9.09 µg/mL). The mixture was vortex-mixed for 5 minutes and centrifuged at 14 000 151 
rpm (14 463 x g) for 10 minutes and 50 µL of the supernatant was injected onto the HPLC system.   152 
 153 
Data analyses 154 
The pharmacokinetic parameters were calculated based on a non-compartmental model. 155 
Peak concentration (Cmax) and time of peak concentration (Tmax) were obtained directly from the 156 
individual plasma concentration-time profiles. The Tlag referred to the lag time to the appearance of 157 
AmpB in the blood after administration. The area under the curve from time zero to last measurable 158 
concentration (AUC0-t) was calculated using trapezoidal method. The AUC from the last measurable 159 
concentration (Ct) to infinity (AUCt-) was calculated by dividing the Ct by k, the apparent elimination 160 
rate constant, which in turn was obtained from the terminal slope of the individual plasma 161 
concentration-time profiles after logarithmic transformation of the plasma concentration values and 162 
application of linear regression. Thus the total (AUC0-) was computed as: 163 
AUC0- = AUC0-t + Ct/k ……………………………………………………………. (1) 164 
The MRT was estimated as follows: 165 
MRT = AUMC0-/ AUC0- ….………………………………………………… (2) 166 
where, AUMC0- is area under the first moment versus time curve which is calculated by adding the 167 
total area from time zero to the last measurable concentration (AUMC0-t) to the area from the last 168 
measurable concentration to time infinity (AUMCt-) of the plasma concentration times time versus 169 
time curves. AUMC0-t was determined using trapezoidal formula while AUMCt- was calculated by 170 
dividing the last concentration times time value with elimination rate constant, k.  171 
The MAT was estimated as follows: 172 
MAT = MRTPO – MRTIV    ……………………………………………………………. (3) 173 
 
where, MRT is the mean residence time, PO is orally administered formulations and IV refers to 174 
administered intravenously. 175 
 176 








……………………………………………………………. (4) 178 
where, AUC is the area under the plasma concentration versus time curve from time zero to infinity, 179 
PO is the oral administration and IV is the intravenous administration.  180 






     ……………………………………………………………. (5) 182 
where, AUCNLC is the area under the curve of plasma concentration versus time curve from time zero 183 
to infinity of rats administered AmpB NLC or ChiAmpB NLC orally and AUCPO is the area under the 184 
curve of plasma concentration versus time curve from time zero to infinity of rats administered 185 
Amphotret® orally. 186 
Statistical analyses 187 
 Statistical evaluation on samples was performed using a one-way analysis of variance 188 
(ANOVA) followed by an independent t-test, where differences were considered significant when p < 189 
0.05. Linearity was evaluated by linear regression analysis, which was calculated by least squares 190 
regression analysis and the ANOVA test. All calculations were conducted using IBM SPSS Statistics 24 191 




REESULTS AND DISCUSSION 195 
Prior to the in vivo studies, a HPLC analysis for AmpB in spiked plasma and tissue 196 
homogenates was developed and validated. The validity of the assay was verified by linear ANOVA 197 
regression analysis, which demonstrated a 95 % confidence level in predicting the outcome (p < 198 
0.05). All the r2 values were 0.996 and above, confirming the linearity of the method over the 199 
concentrations analyzed (Table 1).  200 
Table 1: Linearity and sensitivity of AmpB analytical procedure different biological samples 201 
 202 
r2 is the determination coefficient, LOD is the limit of detection and LOQ is the limit of quantification. 203 
LOD and LOQ of plasma is in µg/mL while for tissue homogenate are in ng/g. *p< 0.05: statistical 204 
significance between the mean peak areas of AmpB/ IS and concentration of AmpB. 205 
 206 
The LOD and LOQ values in plasma samples were 0.0093 and 0.031 µg/mL respectively, 207 
which are comparably more sensitive than in other studies (20–22). The LOD in the tissue samples 208 
were found to be 0.65 ng/g for liver, 0.97 ng/g for kidney, 0.99 ng/g for spleen, 0.95 ng/g for 209 
stomach and 0.87 ng/g for small intestine, are comparatively lower than reported analytical 210 
thresholds for AmpB, suggesting a higher sensitivity (1,23).  211 
From Table 2, the average recoveries of AmpB from the biological samples were more than 212 
80 %, indicative of an efficient extraction procedure (24). High percentage of accuracies were 213 
observed in plasma samples, 94 - 97 % (Table 2) and are in accordance with other reported values 214 
 Equation r2 LOD LOQ 
Plasma y = 0.8769x – 0.0731 0.9962* 0.0093 0.031 
Liver y = 0.0324x + 0.0012 1* 0.65 2.16 
Kidney y = 0.0293x + 0.0412 0.9969* 0.97 3.23 
Spleen y = 0.0341x + 0.0109 1* 0.99 3.32 
Stomach y = 0.0394x + 0.0079 0.9998* 0.95 3.17 
Small intestine y = 0.0306x + 0.0362 0.9989* 0.87 2.88 
 
(21,22). The degree of repeatability was evaluated based on the percentage of coefficient variation 215 
(CV) as illustrated in Table 2.  216 
Table 2 Percentage of recovery, accuracy and precision of AmpB/ IS spiked with plasma and tissue 217 
homogenates (mean ± S.D., n = 3 for recovery and n = 6 for accuracy and precision). 218 
 219 
 220 
Low refers to 0.1 µg/ml in plasma and 2.5 µg/g in tissue samples; medium refers to 1 µg/ml in 221 
















95.3 ± 1.6 78.1 ± 0.7 








100.2 ± 0.8 85.0 ± 0.3 








113.7 ± 0.3 87.6 ± 0.1 
Accuracy 
(%) 






91.8 ± 1.7 98.9 ± 0.4 






93.4 ± 0.4 98.6 ± 0.4 






94.8 ± 0.2 98.6 ± 0.2 
Precision 
(% CV) 
Low 5.89 3.24 5.27 0.64 4.93 0.89 
Medium 1.77 1.06 1.52 1.83 3.77 0.87 







The repeatability (CV) of the method in plasma was between 1.77 - 5.89 % which are well 233 
below the accepted limit of 15 % (23,25). Thus, the developed HPLC method was found to be 234 
accurate and reproducible and hence suitable for evaluation of AmpB concentration in rat tissue. 235 
 In the present study, four formulations of AmpB (orally administered AmpB NLC, ChiAmpB 236 
NLC, Amphotret® (PO) and intravenously administered Amphotret® (IV)) were administered to either 237 
of one of the four groups of Sprague Dawley rats. Sprague Dawley rats were chosen as the animal 238 
model in this study due to anatomical, physiological, drug absorption profile and expression of 239 
transporter enzyme similarities of its intestines to that of the human (26). The plasma concentration-240 
time profiles following the four-way administration to the rats are depicted in Figure 1 while 241 









Table 3 Pharmacokinetic parameters of AmpB from the different formulations (mean ± S.D., n = 3). 250 
 251 
Tmax: time to maximum plasma concentration, Cmax: maximum plasma concentration, AUC0-∞: 252 
area under the curve up to infinity, MRT: mean residence time, MAT: mean absorption time, F: 253 
absolute bioavailability and Fr: relative bioavailability. 254 
*p< 0.05: statistical significance between  255 
a) Amphotret® and developed formulations.  256 





Figure 1: Plasma concentration-time profile of formulations (mean ± S.D., n = 3), n = 2 for the 24-262 
hour time point. Insert is the plasma concentration-time profiles of orally administered formulations.    263 
 
 264 
Upon administration of  ChiAmpB NLC formulation, the plasma concentration of AmpB was 265 
detectable up to 24 hours whereas, for the other formulations, it was only detectable up to 8-hour 266 
post-administration. As expected, the intravenously administered Amphotret® showed a drastic (10-267 
fold) drop in AmpB plasma concentration, from 3.53 ± 1.01 to 0.34 ± 0.2 µg/mL 2-hour post 268 
administration. This is consistent with the results reported in the literature (27,28). 269 
 Orally administered AmpB NLC and ChiAmpB NLC observed lag times (Tlag) of 2 hours (Figure 270 
1), suggesting that there was a delay in the absorption of both formulations in contrast to 271 
Amphotret® (PO). We hypothesize that due to their lipidic characteristics, the observed lag times 272 
were due to the uptake process via lymph, prompted by the mucoadhesive properties of the 273 
formulations (particularly ChiAmpB NLC) in contrast to Amphotret® (PO) formulation as observed in 274 
other studies (12,29). It is normal to observe a lag time of up to 3 hours before a noticeable increase 275 
in concentration of lipids in lymph or plasma as observed in human (30), rats (31) and sheep (32). 276 
 There was a gradual increase in the plasma concentration of AmpB, reaching peak 277 
concentration (Tmax) at approximately 3.6 and 4.7 hours, respectively for orally administered 278 
Amphotret® and AmpB NLC formulations (Table 3). As compared to AmpB NLC, ChiAmpB NLC 279 
showed an additional delay of approximately 1.6 hours before attaining the Tmax. The longer Tmax 280 
exhibited by both NLCs formulations may yet affirm the indirect transport of the NLCs into the 281 
systemic circulation which is in consistent with results observed by vinpocetine-loaded NLCs (33). 282 
The estimation of Tmax is dependent on the frequency of blood sampling which was a constraint in 283 
the present study due to the limitation and impracticability of frequent sampling points in small 284 
rodents like rats. Hence, further interpretation of the data was sought through arithmetic calculation 285 
using statistical moment analysis in order to evaluate their MRTs.  286 
 MRT refers to the duration of residence of the nanoparticles in the body before elimination. 287 
This involves a composite of kinetic processes such as rate and extent of the absorption process, in 288 
 
vivo release of AmpB and the distribution of the AmpB to various part of the body (34). The MRT of 289 
ChiAmpB NLC was 21.61 ± 0.71 hr, which is significantly higher than the Amphotret® (PO), 7.51 ± 290 
0.15 hr (p < 0.05) and AmpB NLC, 7.48 ± 0.67 hr. This suggests that the ChiAmpB NLC remained in 291 
the body longer which is attributable to the mucoadhesive properties of the chitosan coating. The 292 
mucoadhesiveness of ChiAmpB NLC prolonged the GI transit of the particles through retention at the 293 
site of absorption/ uptake as well as a slow, sustained release of AmpB which in concert with our 294 
previous studies (4,14).  295 
 ChiAmpB NLC showed a higher peak plasma concentration (Cmax), 0.40 ± 0.19 µg/mL as 296 
compared to AmpB NLC and Amphotret® (PO), observing Cmax of 0.34 ± 0.03 and 0.31 ± 0.04 µg/mL, 297 
respectively. Besides, ChiAmpB NLC formulation also observed a significantly higher AUC0- (p < 0.05) 298 
as compared to Amphotret® (PO). The AUC0- of AmpB NLC was significantly higher than Amphotret® 299 
(PO) (p < 0.05) but was not significantly different from ChiAmpB NLC even though the latter 300 
observed a higher AUC0-. This is in accordance with other studies (4,12) and suggests that the AmpB 301 
was better absorbed from ChiAmpB NLC than from uncoated AmpB NLC and Amphotret® (PO), 302 
which this was also evident in the relative bioavailability (Fr) of ChiAmpB NLC, which was twice 303 
higher than Amphotret® (PO). 304 
 The higher bioavailability observed by both AmpB NLC and ChiAmpB NLC compared to the 305 
other orally administered AmpB can be explained by the fact that beeswax and coconut oil 306 
promoted the lymphatic transport of the NLCs via uptake by the M-cells overlying the lymphoid 307 
follicles and Peyer’s patches (35,36). This is supported by studies which showed that the oral 308 
absorption of the poorly soluble drugs was enhanced with co-administration with lipids whereby the 309 
lymphatic pathway plays a crucial role (12,37). Studies by Yuan et al. (37) showed that up to 77.9 % 310 
of lipid nanoparticles were absorbed through the lymphatic pathway while the remaining was 311 
transported via the portal blood vein. With the lymphatic intestinal pathway, the first pass 312 
metabolism in the liver was avoided and thus, bioavailability of the drug was improved.  313 
 
 The incorporation of chitosan coating on the surface of the NLCs is perceived to protect 314 
AmpB from the harsh GI environment and thus promotes the uptake by the intestinal lymphatics. 315 
Due to the positive charge rendition of chitosan in ChiAmpB NLCs, the NLCs promotes penetration 316 
into the negatively charged mucosal layer and through this adhesion, the AmpB was slowly released 317 
from the system (14). Thus, the increase in residence time and intimate contact of the chitosan-318 
coated NLC with the wall of the small intestine provided the requisite for improved AmpB 319 
absorption. This is in agreement with findings that there was an enhancement in the uptake of 320 
chitosan-coated nanospheres by the gut tissue (4,38). Furthermore, other drug compounds such as 321 
insulin (39), ferrous sulphate (40) and doxorubicin (41) also showed improvement in the respective 322 
absorptions through the incorporation of chitosan coating to lipid nanoparticles. Positively charged 323 
nanoparticles improved the bioavailability of cyclosporine A in dogs (42) and progesterone in rats 324 
(43). 325 
 As mucoadhesion was believed to be a prerequisite for the improved bioavailability of the 326 
AmpB, further investigation on the amount of AmpB in stomach and the small intestine over the GI 327 
transit course of the NLCs was conducted. After 6 hours, most of the AmpB from AmpB NLC was 328 
found in the small intestine (73.1 ± 0.2 µg/g) whereas the AmpB from ChiAmpB NLC was 329 
predominantly found in the stomach (15.4 ± 0.1 µg/g) (Figure 2).  330 
 
 331 
Figure 2: Concentration of AmpB in stomach and small intestine over 6-24 hour-post administration 332 
(mean ± S.D., n = 3), *p < 0.05: statistical significance between 6 and 8-hour values.  333 
 334 
AmpB was undetectable in the stomach after 24 hours which suggests that all the formulations had 335 
emptied into the small intestine by this time. However, AmpB remained detectable in the small 336 
intestine of the rats treated with AmpB NLC and ChiAmpB NLC formulations 24-hour post 337 
administration which suggest that the GI transit for both formulations were more than 24 hours in 338 
contrast to the normal reported rats GI transit time of 12 - 16 hours (44,45). A significant drop (p < 339 
0.05) in the concentration of AmpB was observed in the intestinal tissue in rats treated with AmpB 340 
NLC, from 73.1 ± 0.2 to 10.2 ± 0.4 µg/g between 6 to 8-hour post administration, respectively. A 341 
further drop in the concentration was observed from AmpB NLC between 8 to 24-hour post 342 
administration, reaching a final concentration of 6.6 ± 0.3 µg/g (Figure 2). It is interesting to note 343 
that AmpB NLCs was detectable in the small intestine 24-hour post administration which can be 344 
explained by the small size dimensions of AmpB NLCs with a concomitant increase in surface area, 345 
which together, enhanced the interactive forces at play during mucoadhesion (11,13).  346 
 
On the other hand, the ChiAmpB NLC observed only minimal changes to the concentration 347 
of AmpB in the small intestine, with differences of about 4.6 and 1.0 µg/g between 6 - 8 hours and 8 348 
- 24 hours. Furthermore, ChiAmpB NLC observed a higher concentration of AmpB (7.1 ± 0.6 µg/g) 349 
post 24-hour administration as compared to AmpB NLC, believed to be due to additional 350 
mucoadhesive power provided by the chitosan coating. The preceding accords well with the results 351 
from the pharmacokinetics studies (Table 3), in which ChiAmpB NLC recorded a longer MAT 352 
compared to AmpB NLC, attributable to prolong residence time of the particles at the absorption 353 
site.  354 
One of the major limitations to the clinical applications of the AmpB is its nephrotoxicity. 355 
Figure 3 show that Amphotret® (IV) marked a five-fold higher accumulation of AmpB in the kidneys 356 
in contrast to ChiAmpB NLC at 8-hour post administration.  357 
 358 
 359 
Figure 3: Tissue distribution of AmpB in rats administered with different formulations over 360 
time (mean ± S.D., n = 3), *p < 0.05: statistical significance between Amphotret®(IV) and 361 
ChiAmpB NLC as well as AmpB NLC formulations 362 
 363 
 
On the other hand, ChiAmpB NLC showed the lowest renal disposition at 4.0 ± 0.9 µg/g 364 
followed by AmpB NLC and Amphotret® (PO), at 5.1 ± 0.2 and 5.9 ± 1.4 µg/g, respectively. 365 
Amphotret® (IV) continued to show preferential disposition in the kidneys 24-hour post 366 
administration, significantly (p < 0.05) higher than from ChiAmpB NLC and AmpB NLC formulations. 367 
This is in accordance with reports which showed that Amphotret® (IV) was more nephrotoxic than 368 
orally administered lipid-based formulations of AmpB (1,12). 369 
 We believe that the observed difference in the renal disposition of AmpB was due to the 370 
aggregation states of AmpB whereby, Amphotret® exhibited the dimer configuration whilst AmpB in 371 
the NLCs formulations exhibited the polyaggregate states (13). Studies by Espada et al. (46) revealed 372 
that the dimer state of AmpB showed preferential disposition in the kidneys and observed mostly, 373 
unilateral kidney atrophy in mice while the polyaggregate states of AmpB conserved both kidneys 374 
with a normal size and appearance. Based on these results, it is likely we can conclude that the low 375 
renal tissue levels of AmpB in rats treated with ChiAmpB NLC may demonstrate a lower 376 
nephrotoxicity potential and thus, may establish a safer toxicity profile than current marketed 377 
formulations (3). 378 
The liver and spleen are part of the RES organs which are target organs for fungal infections 379 
as well as intracellular parasites of Leishmaniasis genus (27). IV administration of Amphotret® to rats 380 
registered the highest concentration of AmpB in both liver and spleen, followed by oral 381 
administration of Amphotret®, AmpB NLC and ChiAmpB NLC 8-hour post administration (Figure 3). 382 
The possible  reason for this phenomenon has to do with the high blood perfusion to these organs 383 
and/or the high uptake of the cells in the RES-type organs (47). 384 
 However, the clearance of AmpB from liver and spleen was faster in rats treated with 385 
Amphotret® (IV), falling drastically to 10.2 ± 0.2 and 8.4 ± 0.3 µg/g in liver and spleen, respectively 386 
24-hour post administration. This indicates that the uptake of the Amphotret® (IV) by the RES cells 387 
was not significant (47). On the other hand, a three-fold increase in AmpB accumulation in both liver 388 
 
and spleen following administration of ChiAmpB NLC was observed at 24 hours. This is in contrast to 389 
the uncoated AmpB NLC, which showed undetectable amount of AmpB in the spleen. The presence 390 
of a high AmpB deposition in the liver and spleen in rats administered with ChiAmpB NLC serves the 391 
possibility of utilizing the former in visceral Leishmaniasis.  392 
 393 
CONCLUSION 394 
 In summary, ChiAmpB NLC demonstrated an improvement in the oral bioavailability of 395 
AmpB compared to the uncoated AmpB NLC and Amphotret® (delivered orally or intravenously). 396 
This improved bioavailability appears to be a culmination of factors including prolonged retention of 397 
ChiAmpB NLC within the small intestine, absorption via intestinal lymphatic pathway, hence 398 
avoidance of first hepatic clearance and a slow, sustained release of AmpB from ChiAmpB NLC. 399 
Furthermore, the ChiAmpB NLC presents a lower risk for nephrotoxicity and higher accumulation in 400 
the liver and spleen. Thus, not only have the limitations inherent with the current mode of AmpB 401 
administration been addressed but also, a clinical targeted strategy is a possibility in the treatment 402 
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